Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Genome-wide CRISPR-Cas9 screen reveals novel ruxolitinib-resistance targets in myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

TZTian ZengZZZhikang ZhengJHJian Huang

Discussion

Loading...

Member takes

Overview

Genome-wide analysis uncovers resistance genes in myeloproliferative neoplasms, suggesting new therapeutic targets for ruxolitinib treatment.

Key Points

  • Ruxolitinib resistance is linked to key genetic targets identified through CRISPR-Cas9 screening.
  • Next-generation sequencing revealed essential and resistance-associated genes in myeloproliferative neoplasms.
  • The study highlights roles of cell cycle regulation and oxidative stress response in drug resistance.
  • Findings suggest a need for multi-target approaches to overcome ruxolitinib resistance, enhancing treatment options.

Cite This Study

Zeng et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8f2https://doi.org/10.1182/blood-2025-7286
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Unravelling molecular determinants of ruxolitinib treatment response in myelofibrosis using single cell multiomics2025 · 1 citations
  2. 2Preclinical efficacy of the synergistic Ruxolitinib–Homoharringtonine combination in TP53-mutated myeloproliferative neoplasms progressing to sAML2025
  3. 3Direct small molecule inhibition of RAS enhances JAK2 inhibitor therapy in preclinical models of myeloproliferative neoplasms2025
  4. 4Decitabine enhances the cytotoxic effect of ruxolitinib in myeloproliferative neoplasms by targeting SR splicing factors2025
  5. 5Single-cell transcriptomic studies reveal altered heterogeneity in CD41 enriched megakaryocytes after targeted therapy in myeloproliferative neoplasm2025